RVL Pharmaceuticals plc Annual Current Federal Tax Expense (Benefit) in USD from 2017 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
RVL Pharmaceuticals plc quarterly/annual Current Federal Tax Expense (Benefit) history and growth rate from 2017 to 2022.
  • RVL Pharmaceuticals plc Current Federal Tax Expense (Benefit) for the quarter ending March 31, 2023 was $4.1M.
  • RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2022 was -$86K, a 55.2% increase from 2021.
  • RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2021 was -$192K, a 105% decline from 2020.
  • RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2020 was $4.15M.
Current Federal Tax Expense (Benefit), Annual (USD)
Current Federal Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$86K +$106K +55.2% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-20
2021 -$192K -$4.34M -105% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 $4.15M +$21.1M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
2019 -$17M -$19.9M -685% Jan 1, 2019 Dec 31, 2019 8-K 2021-09-08
2018 $2.9M +$1.16M +66.3% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-19
2017 $1.75M Jan 1, 2017 Dec 31, 2017 8-K 2019-12-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.